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in primary advanced renal cell tumors: Cutting edges
for cutting-edge surgeryWith great interest we have read the article entitled
“Pathologic response and surgical outcomes in patients
undergoing nephrectomy following receipt of immune
checkpoint inhibitors for renal cell carcinoma” by Singla
et al. In their article, Singla et al report that cytoreductive
nephrectomy following systemic treatment with immune
checkpoint inhibitors (ICI) appears safe in patients with
advanced or metastatic renal cell carcinoma (RCC) [1]. In
their cohort, pathological responses of primary RCC to nivo-
lumab § ipilimumab were observed. As these pathological
responses are remarkable for primary RCC, the question rises
whether ICIs could be effective as neoadjuvant therapy.
To answer this question, we here illustrate the efficacy
of nivolumab plus ipilimumab in unresectable primary
RCC. In a 74-year old patient, cT3aN1M0 RCC of clear
cell histology was considered unresectable due to regional
lymphadenopathy compressing the tumor thrombus in the
renal vein (Fig. 1). First-line nivolumab (3 mg/kg) and
ipilimumab (1 mg/kg) was started and after four 3-week
cycles, a partial response according to RECIST v1.1 [2]
was observed with disappearance of lymphadenopathy,
42% reduction of the primary tumor and a near-complete
response of the tumor thrombus. As the primary tumor
was considered resectable, open radical nephrectomy was
performed. No vital tumor cells could be detected byFig. 1. Primary RCC in the left kidney with enlarged regional lymph nodes and
cycles of nivolumab and ipilimumab (middle). Histopathological examination of
shows sclerotic connective tissue with hemosiderin pigment and lymphocytic infi
carcinoma.
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1078-1439/ 2020 Elsevier Inc. All rights reserved.histopathological examination (ypT0N0). After nephrec-
tomy, systemic therapy was discontinued and active surveil-
lance was started. Until now, at 5 months after nephrectomy,
there is no evidence of disease.
Since the introduction of ICIs, the treatment strategies in
RCC patients are dramatically changing. As an increasing
number of RCC patients will experience durable tumor
responses in both primary tumor and metastases after ICIs,
delayed nephrectomy will be considered more often [3−5].
During first-line combination treatment with ICIs, the
rate and depth of primary tumor response is significantly
improved as compared with first-line monotherapy tyrosine
kinase inhibitors [3,4]. For the first time, we have illustrated
that ICIs even facilitate nephrectomy by transforming unre-
sectable to resectable primary RCC [1] and induce complete
pathological responses in primary RCC. As ICIs obviously
have neoadjuvant potential for the treatment of primary
RCC, treatment with ICIs should be considered prior to
cytoreductive nephrectomy.Conflicts of interest
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